Clinical trials: SGLT 2 Inhibitors
Glomerulonephritis, Immunoglobulin A Nephropathy
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
Idiopathic immunoglobulin A nephropathy (IgAN) is the most common biopsy-proven glomerulonephritis in the world. Approximately 40% of IgAN patients reach end-stage kidney disease (ESKD) 20 years after their kidney biopsy.
- Trial name
- CLIgAN (NCT04662723)
- Testing
- Corticosteroid, Renin-angiotensin sytem blockers, Sodium-glucose cotransporter 2 inhibitor
- Where
- 2 sites in Italy
- Volunteers
- 878 people
- Sponsor
- Fondazione Schena
Cancer, Diabetes Mellitus, Type 2
SGLT2 Inhibitors and Reducing the Risk of Cancers Among Diabetics , an Observational Study
Since the discovery of SGLT2 inhibitors, there is a great shift in diabetic treatment, so this drug is magic, this drug can reduce the blood sugar level by blocking the reabsorption of glucose in the kidney and increasing glucose…
- Conditions
- Cancer, Diabetes Mellitus, Type 2, Interleukin 6, SGLT2 Inhibitors
- Trial name
- NCT05612269
- Testing
- interleukin 6
- Where
- Saudi Arabia
- Volunteers
- 200 people
- Sponsor
- Ministry of Health, Saudi Arabia
Hypertension (HTN)
Finerenone and Empagliflozin Combination in Obesity With Hypertension: A 12-Week Prospective, Parallel-design, Double-blind, Randomized, Placebo-controlled Trial
The EFFORT Study (Empagliflozin and Finerenone Combination in Obesity with Hypertension) is a 12-week, randomized, double-blind, placebo-controlled trial that aims to test whether combining empagliflozin (10 mg/day) with…
- Trial name
- NCT07678151
- Testing
- Empagliflozin and Finerenone
- Where
- 2 sites in China
- Volunteers
- 260 people
- Sponsor
- Heart Health Research Center
Transthyretin Amyloid Cardiomyopathy
SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy
This is a single center, single arm, prospective, 12 week open label pilot trial of the sodium-glucose cotransporter 2 inhibitor (SGLT2i), empagliflozin 10 mg oral daily, in patients with transthyretin amyloid cardiomyopathy…
- Trial name
- NCT05233163
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
Sepsis, Septic Shock
Impact of Prior SGLT2 Inhibitors Use on the Development and Progression of Sepsis-Associated Acute Kidney Injury
The primary objective of this study is to investigate whether using SGLT2i may be associated with decreased incidence of sepsis-induced AKI or not.
- Conditions
- Sepsis, Septic Shock, Acute Kidney Injury
- Trial name
- NCT06902493
- Testing
- No intervention
- Where
- Saudi Arabia
- Volunteers
- 664 people
- Sponsor
- University of Jazan
Diabetes Mellitus
Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore
To evaluate clinical effectiveness and safety of Singaporean Type 2 Diabetes mellitus patients administered SGLT 2 inhibitor monotherapy or in combination with other commonly used hypoglycaemic drugs in real life clinical…
- Trial name
- NCT02578563
- Where
- Singapore
- Volunteers
- 201 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1, Hypoglycemia
Effect of Dapagliflozin on IAH in T1DM
Approximately 25% of patients with type 1 diabetes have lost the capacity to timely detect hypoglycaemia, a condition referred to as impaired awareness of hypoglycaemia (IAH) that causes a six-fold higher risk of severe…
- Conditions
- Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
- Trial name
- NCT03556033
- Testing
- Dapagliflozin
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Radboud University Medical Center
Diabete Mellitus
Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients
Total of 360 participants were enrolled and prescribed oral 200 mg SGLT-2 tablet. All participants were followed-up for about three months.
- Trial name
- NCT07367555
- Testing
- Oral 100 gram Empagliflozin tablet along with diet plan and exercise, Diet plan and exercise
- Where
- Pakistan
- Volunteers
- 360 people
- Sponsor
- Ariba Shafiq
Diabetes Mellitus, Type 2, Coronary Artery Disease
SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)
Patients with type 2 diabetes mellitus (DM) have higher risk of major cardiovascular events (MACE) and renal disfunction. The Sodium-glucose cotransporter-2 inhibitors (iSGLT2) reduces hyperglycemia in patients with type 2 DM and…
- Conditions
- Diabetes Mellitus, Type 2, Coronary Artery Disease, Acute Kidney Injury
- Trial name
- SAFE-PCI (NCT05037695)
- Testing
- empagliflozin 25 MG
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- University of Sao Paulo General Hospital
Anemia in CKD Patients
Effect of SGLT2 Inhibitors on Anemic CKD Patients
anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its…
- Trial name
- NCT07334145
- Testing
- SGLT2 inhibitor
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sohag University
Type 2 Diabetes
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
This study is a multicenter, randomized, open-label, parallel-group, semaglutide injection-controlled clinical trial. It aims to evaluate the non-inferiority of UBT251 Injection in glycemic control compared with Semaglutide…
- Trial name
- UNIGUIDE-2 (NCT07653477)
- Testing
- UBT251 Injection 2.0 mg group, UBT251 Injection 4.0 mg group, UBT251 Injection 6.0 mg group
- Where
- China
- Volunteers
- 956 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Diabetes Mellitus, Type 2
An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
The main purpose of this study is to assess the effects of 4 weeks each of daily treatment with canagliflozin 300 milligram (mg) versus sitagliptin 100 mg as treatment adjuncts to metformin (at stable dosages) on intrapatient…
- Trial name
- COMETA (NCT03267576)
- Testing
- Canagliflozin 300 mg, Sitagliptin 100 mg, Metformin
- Where
- 5 sites in Mexico
- Volunteers
- 64 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Gout
Pharmacogenetics of SGLT2 Inhibitors
Sodium-dependent glucose transporter-2 (SGLT2) inhibitors are a new class of anti-diabetic drugs, which increase urinary glucose excretion thereby promoting weight loss and decreasing plasma glucose levels.
- Conditions
- Diabetes Mellitus, Gout, Hyperuricemia
- Trial name
- SGLT2iPGx (NCT02462421)
- Testing
- Canagliflozin
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Type 2 Diabetes
A Phase 3 Study of HS-20094 in Patients With T2DM
The study is being conducted to evaluate the efficacy and safety of HS-20094 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors…
- Trial name
- NCT07156539
- Testing
- HS-20094 Injection, Dulaglutide Injection
- Where
- 2 sites in China
- Volunteers
- 546 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Type2 Diabetes
Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES
The current study aims to explore the clinical effects and mechanistics of mono- and combination therapy with SGLT-2 inhibitor empagliflozin and DPP-4 inhibitor linagliptin on renal physiology and biomarkers in metformin-treated…
- Trial name
- RACELINES (NCT03433248)
- Testing
- EMPA/LINA 10/5 mg QD (n=22), LINA/EMPA 5/10 mg QD (N=22), Gliclazide 30 mg QD/BID (N=22)
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- M.H.H. Kramer
Type 2 Diabetes Mellitus
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as dulaglutide when added to sodium-glucose co-transporter 2 (SGLT2) inhibitors in participants with type 2 diabetes mellitus.
- Trial name
- AWARD-10 (NCT02597049)
- Testing
- Dulaglutide, SGLT2 inhibitor, Metformin
- Where
- 41 sites in United States, Austria and 7 more
- Volunteers
- 424 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
The trial is conducted in Asia, Europe, North America and South America. The aim of the study is to compare the effect of liraglutide 1.8 mg/day versus placebo as add-on to an SGLT2 inhibitor with or without metformin on…
- Trial name
- NCT02964247
- Testing
- liraglutide
- Where
- 82 sites in United States, Brazil and 5 more
- Volunteers
- 303 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Diabetic Kidney Disease
Mechanism of SGLT2 Inhibition in the Kidney
The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in…
- Trial name
- NCT06291155
- Testing
- SGLT2 inhibitor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan
Myocardial Infarction, Diabetes Mellitus, Type 2
SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study
Prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that SGLT2 inhibitors reduce cardiovascular risk.
- Trial name
- RECORD-AMI (NCT05770687)
- Testing
- SGLT2 inhibitor
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Kiyuk Chang
ACS (Acute Coronary Syndrome), SGLT2 Inhibitors
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF
The goal of this clinical trial is to learn if dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), can reduce coronary artery inflammation in people with acute coronary syndrome (ACS) who do not have diabetes or…
- Trial name
- DAPA-PCAT (NCT07351643)
- Testing
- Dapagliflozin
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Shenyang Northern Hospital